Roth Capital Lowers Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target to $70.00

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) had its price objective cut by Roth Capital from $101.00 to $70.00 in a research note issued to investors on Wednesday, The Fly reports.

ENTA has been the subject of a number of other reports. Zacks Investment Research upgraded Enanta Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, February 18th. SVB Leerink lowered their target price on Enanta Pharmaceuticals from $80.00 to $68.00 and set a market perform rating for the company in a research report on Wednesday, February 9th. StockNews.com started coverage on Enanta Pharmaceuticals in a research report on Thursday, March 31st. They set a hold rating for the company. Finally, JMP Securities restated a buy rating and set a $116.00 price target on shares of Enanta Pharmaceuticals in a report on Wednesday, March 30th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of Hold and an average target price of $87.88.

NASDAQ:ENTA traded up $0.31 during mid-day trading on Wednesday, reaching $51.81. The company’s stock had a trading volume of 419 shares, compared to its average volume of 213,842. Enanta Pharmaceuticals has a 12-month low of $40.37 and a 12-month high of $102.00. The firm’s fifty day moving average price is $68.02 and its two-hundred day moving average price is $71.52. The stock has a market cap of $1.06 billion, a P/E ratio of -10.34 and a beta of 0.64.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last announced its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($1.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.20). Enanta Pharmaceuticals had a negative net margin of 108.39% and a negative return on equity of 24.62%. During the same period in the prior year, the company earned ($1.09) EPS. On average, sell-side analysts anticipate that Enanta Pharmaceuticals will post -5.78 EPS for the current year.

In other Enanta Pharmaceuticals news, VP Nathalie Adda sold 50,559 shares of the firm’s stock in a transaction dated Friday, April 1st. The stock was sold at an average price of $71.23, for a total value of $3,601,317.57. Following the completion of the sale, the vice president now owns 34,982 shares of the company’s stock, valued at $2,491,767.86. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Bruce L. A. Carter sold 6,000 shares of the firm’s stock in a transaction dated Monday, March 21st. The stock was sold at an average price of $67.83, for a total value of $406,980.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 113,683 shares of company stock worth $8,084,777. 12.42% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC raised its position in Enanta Pharmaceuticals by 19.5% during the first quarter. FMR LLC now owns 240,195 shares of the biotechnology company’s stock valued at $22,944,000 after acquiring an additional 39,200 shares in the last quarter. First Trust Advisors LP raised its position in Enanta Pharmaceuticals by 11.9% during the first quarter. First Trust Advisors LP now owns 25,234 shares of the biotechnology company’s stock valued at $2,410,000 after acquiring an additional 2,681 shares in the last quarter. Royal Bank of Canada raised its position in Enanta Pharmaceuticals by 1,367.7% during the second quarter. Royal Bank of Canada now owns 1,409 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 1,313 shares in the last quarter. Wells Fargo & Company MN raised its position in Enanta Pharmaceuticals by 392.4% during the second quarter. Wells Fargo & Company MN now owns 20,665 shares of the biotechnology company’s stock valued at $910,000 after acquiring an additional 16,468 shares in the last quarter. Finally, Morgan Stanley raised its position in Enanta Pharmaceuticals by 20.8% during the second quarter. Morgan Stanley now owns 176,207 shares of the biotechnology company’s stock valued at $7,756,000 after acquiring an additional 30,356 shares in the last quarter. 98.87% of the stock is owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals (Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Read More

The Fly logo

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.